FDA Chief open to rethinking incentives on orphan drugs

(Credit: Shutterstock/science photo)

The commissioner of the Food and Drug Administration questions whether the right financial incentives are in place for drugmakers who develop orphan drugs for rare diseases.

In an interview this week, the FDA’s Scott Gottlieb said the Orphan Drug Act of 1983 has provided “an enormous amount of public health value” over the years, but the “market has changed.”

Gottlieb said it’s time to ask the question: “Do we have the right incentives in...

What feeling does this article give you?

#hashtags to follow:

Shutterstock [+]    Food and Drug Administration [+]    FDA [+]    Scott Gottlieb [+]    Orphan Drug Act [+]    Gottlieb [+]   

More #news: